SEP 17, 2020 7:50 PM PDT

A Biomarker May Predict the Most Severe COVID-19 Cases

WRITTEN BY: Carmen Leitch

Researchers may have found a way to identify the COVID-19 patients that will need targeted therapies the most. Biomarkers have been discovered that may help clinicians determine who is at risk for having a serious illness from the pandemic virus SARS-CoV-2. The work, which may help doctors save lives, has been reported in Frontiers in Immunology.

Colorized scanning electron micrograph of an apoptotic cell (tan) heavily infected with SARS-CoV-2 virus particles (orange), isolated from a patient sample. Image captured at the NIAID Integrated Research Facility (IRF) in Fort Detrick, Maryland. / Credit: NIAID

The researchers began by assessing how people's immune systems were responding to SARS-CoV-2 infections, which can range from mild to life-threatening. The immune system has to be very carefully controlled; its response to an invader can overwhelm the body if it's not managed properly. The scientists analyzed RNA sequencing data, which provides a snapshot of the genes that are active in a cell at some given time; in this case, airway cells from healthy individuals and various COVID-19 patients. This publicly available data has been published in previous research by Chinese scientists.

"Our analyses identified an association between immune cells called neutrophils and special cell receptors that bind to the steroid hormone glucocorticoid," explained Professor Heung Kyu Lee of The Korea Advanced Institute of Science and Technology (KAIST). "This finding could be used as a biomarker for predicting disease severity in patients and thus selecting a targeted therapy that can help treat them at an appropriate time," he added.

In some severe COVID-19 cases, an exaggerated immune response has been linked to inflammation that is so excessive it damages the airways. This condition is called acute respiratory distress syndrome (ARDS), and it is responsible for an estimated 70 percent of fatal COVID-19 infections. The mechanisms underlying this problem are not well understood, but it seems to involve an excess of immune cells called neutrophils in the airways.

Lee and KAIST graduate candidate Jang Hyun Park found that immune cells called myeloid cells generate too many molecules like a chemokine called CXCL8 or cytokine called TNF, which recruit neutrophils. Severely ill patients are also not good at recruiting the T cells that have to help attack the virus. Neutrophils themselves can secrete molecules that trap pathogens at normal levels, but cause damage to the airways when the levels are too high.

Increased expression of CXCL8 and excess neutrophil recruitment were also linked to a lack of glucocorticoid receptors.

Glucocorticoids, including dexamethasone, can help stop inflammation. While they may help severely ill COVID-19 patients, if they are used too early or in mild infections, they may suppress the natural immune response to the virus. Glucocorticoid treatment may also be useless for people that already have airway damage.

It will be important to know exactly who benefits from the treatment, like COVID-19 patients with low glucocorticoid receptor expression, high CXCL8 levels, and excess neutrophil recruitment. More work will be needed before these findings can be taken to the clinic, but it can help us learn more about preventing the worst cases of COVID-19.

"Our study could serve as a springboard towards more accurate and reliable COVID-19 treatments," Professor Lee said.


Sources: AAAS/Eurekalert! via The Korea Advanced Institute of Science and Technology, Frontiers in Immunology

About the Author
  • Experienced research scientist and technical expert with authorships on over 30 peer-reviewed publications, traveler to over 70 countries, published photographer and internationally-exhibited painter, volunteer trained in disaster-response, CPR and DV counseling.
You May Also Like
JUL 26, 2020
Neuroscience
How COVID-19 Causes Loss of Smell
JUL 26, 2020
How COVID-19 Causes Loss of Smell
Temporary loss of smell, known as anosmia, is one of the most common early indicators of COVID-19. Although some say it ...
JUL 29, 2020
Immunology
Immune Variation Explains Different COVID-19 Outcomes
JUL 29, 2020
Immune Variation Explains Different COVID-19 Outcomes
Immune systems respond differently to coronavirus infection. People experience the disease causes by coronavirus, COVID- ...
NOV 06, 2020
Immunology
The Coronavirus Is No Match Against Sybody 23
NOV 06, 2020
The Coronavirus Is No Match Against Sybody 23
The virus that causes COVID-19, SARS-CoV-2, uses its spike protein to gain access to cells, by binding to the ACE2 recep ...
DEC 01, 2020
Clinical & Molecular DX
Breathing New Life Into COVID Diagnostics
DEC 01, 2020
Breathing New Life Into COVID Diagnostics
Widespread diagnostic testing capacities are an absolutely critical tool for countries battling the pandemic. For now, m ...
JAN 06, 2021
Clinical & Molecular DX
COVID Patients Can't Stop and Smell the Roses
JAN 06, 2021
COVID Patients Can't Stop and Smell the Roses
A study of over 2,500 European patients has revealed that 85.9 percent of those with mild COVID-19 symptoms lost their s ...
JAN 23, 2021
Cancer
Quantifying delays in radiotherapy during the pandemic
JAN 23, 2021
Quantifying delays in radiotherapy during the pandemic
Researchers from the University of Leeds, Public Health England, and the Royal College of Radiologists have investigated ...
Loading Comments...